+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Australia and New Zealand Healthcare CROs Market Report and Forecast 2025-2034

  • PDF Icon

    Report

  • 200 Pages
  • July 2025
  • Region: Australia, New Zealand
  • Expert Market Research
  • ID: 6163136
The Australia and New Zealand healthcare CROs market size was valued at USD 1.12 Billion in 2024, driven by the rising awareness about the advantages of CROs across the globe. The market size is anticipated to grow at a CAGR of 12.10% during the forecast period of 2025-2034 to achieve a value of USD 3.51 Billion by 2034.

Healthcare CROs: Introduction

In the field of life sciences, contract research organization (CRO) is a company that outsource their research services on a contract basis to pharmaceutical, biotechnology, and medical device organizations. The services provided by CRO may include biopharmaceutical development, biological assay development, commercialization, clinical development, clinical trials management, pharmacovigilance, and research outcomes.

CROs are designed to be cost effective for companies that are developing new medicines and drugs in specified healthcare markets. The major purpose of a CRO is to simplify entry of other pharmaceutical or biotechnology companies into drug markets and simplify the development process of drugs for them in accordance with their requirement. CROs also help foundations, universities, and research institutions with governmental organizations, such as the NIH and EMA, among others. Many CROs certainly provide clinical-study and clinical-trial support for drugs and/or medical devices as well.

Australia and New Zealand Healthcare CROs Market Analysis

The increasing practices of outsourcing of services by pharmaceutical and biotechnology companies in Australia and New Zealand to reduce their expenditure upon the possession of equipment and their maintenance is a major factor influencing the market growth. The increasing demand for oncology research in countries is driving the Australia and New Zealand healthcare CROs market growth. The increasing prevalence of cancer in the countries is justifying the rising demand of oncology research in the countries as there is a surging demand for personalized treatment on the market. The increasing digitization of CROs in Australia and New Zealand is also supporting the increasing demand.

Australia and New Zealand Healthcare CROs Market Segmentations

Australia and New Zealand Healthcare CROs Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Phase Type

  • Drug Discovery
  • Preclinical
  • Clinical

Market Breakup by Indication

  • Oncology
  • Cardiovascular
  • Autoimmune/Inflammation
  • Central Nervous System (CNS)
  • Dermatology
  • Infectious Diseases
  • Respiratory
  • Others

Australia and New Zealand Healthcare CROs Market Overview

The increasing adoption of advanced technologies in the healthcare sector of Australia and New Zealand is contributing to the market growth. The market is witnessing significant growth and is expected to keep growing in coming years as well. This market growth is supported by the rising strategic initiatives such as geographical expansions of CROs. The increasing collaborations among key players in the market are also expected to drive the market growth. The continuous research and development activities are also contributing to the market expansion. The cost-effectiveness which is provided by the CROs and favourable environment for clinical trials as they are equipped with all the necessary requirements for such purposes are a few key factors among others, boosting the for Australia and New Zealand Healthcare CROs market demand.

The revenue growth in the healthcare contract research organizations has also been boosted by the adoption of virtual clinical trials which is most in action since pandemic. The adoption of virtual technologies to streamline clinical research services by CROs is also expected to justify the market growth. The significant advancements taking place in the market to speed up and update the clinical trials is expected to escalate the market growth.

Australia and New Zealand Healthcare CROs Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • PAREXEL International Corporation
  • Thermo Fischer Scientific, Inc.
  • SGS SA
  • ICON plc
  • Medpace Australia Pty. Ltd
  • Charles River Laboratories International, Inc.
  • IQVIA
  • Novotech
  • Laboratory Corporation of America Holdings
  • Syneos Health

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Australia and New Zealand Healthcare CROs Market Overview
3.1 Australia and New Zealand Healthcare CROs Market Historical Value (2018-2024)
3.2 Australia and New Zealand Healthcare CROs Market Forecast Value (2025-2034)
4 Australia and New Zealand Healthcare CROs Market Landscape
4.1 Lentiviral Vectors: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Lentiviral Vectors: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Applications
5 Australia and New Zealand Healthcare CROs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Australia and New Zealand Healthcare CROs Market Segmentation
6.1 Australia and New Zealand Healthcare CROs Market by Phase Type
6.1.1 Market Overview
6.1.2 Drug Discovery
6.1.3 Preclinical
6.1.4 Clinical
6.2 Australia and New Zealand Healthcare CROs Market by Indication
6.2.1 Market Overview
6.2.2 Oncology
6.2.3 Cardiovascular
6.2.4 Autoimmune/Inflammation
6.2.5 Central Nervous System (CNS)
6.2.6 Dermatology
6.2.7 Infectious Diseases
6.2.8 Respiratory
6.2.9 Others
7 Australia and New Zealand Healthcare CROs Market
7.1 Market Share by Country
7.2 Australia
7.3 New Zealand
8 Funding and Investment Analysis
8.1 Analysis by Funding Instances
8.2 Analysis by Type of Funding
8.3 Analysis by Funding Amount
8.4 Analysis by Leading Players
8.5 Analysis by Leading Investors
8.6 Analysis by Geography
9 Partnership and Collaborations Analysis
9.1 Analysis by Partnership Instances
9.2 Analysis by Type of Partnership
9.3 Analysis by Leading Players
9.4 Analysis by Geography
10 Supplier Landscape
10.1 PAREXEL International Corporation
10.1.1 Financial Analysis
10.1.2 Product Portfolio
10.1.3 Demographic Reach and Achievements
10.1.4 Mergers and Acquisitions
10.1.5 Certifications
10.2 Thermo Fischer Scientific, Inc.
10.2.1 Financial Analysis
10.2.2 Product Portfolio
10.2.3 Demographic Reach and Achievements
10.2.4 Mergers and Acquisitions
10.2.5 Certifications
10.3 SGS SA
10.3.1 Financial Analysis
10.3.2 Product Portfolio
10.3.3 Demographic Reach and Achievements
10.3.4 Mergers and Acquisitions
10.3.5 Certifications
10.4 ICON plc
10.4.1 Financial Analysis
10.4.2 Product Portfolio
10.4.3 Demographic Reach and Achievements
10.4.4 Mergers and Acquisitions
10.4.5 Certifications
10.5 Medpace Australia Pty. Ltd
10.5.1 Financial Analysis
10.5.2 Product Portfolio
10.5.3 Demographic Reach and Achievements
10.5.4 Mergers and Acquisitions
10.5.5 Certifications
10.6 Charles River Laboratories International, Inc.
10.6.1 Financial Analysis
10.6.2 Product Portfolio
10.6.3 Demographic Reach and Achievements
10.6.4 Mergers and Acquisitions
10.6.5 Certifications
10.7 IQVIA
10.7.1 Financial Analysis
10.7.2 Product Portfolio
10.7.3 Demographic Reach and Achievements
10.7.4 Mergers and Acquisitions
10.7.5 Certifications
10.8 Novotech
10.8.1 Financial Analysis
10.8.2 Product Portfolio
10.8.3 Demographic Reach and Achievements
10.8.4 Mergers and Acquisitions
10.8.5 Certifications
10.9 Laboratory Corporation of America Holdings
10.9.1 Financial Analysis
10.9.2 Product Portfolio
10.9.3 Demographic Reach and Achievements
10.9.4 Mergers and Acquisitions
10.9.5 Certifications
10.10 Syneos Health
10.10.1 Financial Analysis
10.10.2 Product Portfolio
10.10.3 Demographic Reach and Achievements
10.10.4 Mergers and Acquisitions
10.10.5 Certifications
11 Key Opinion Leaders (KOL) Insights (Additional Insight)
12 Company Competitiveness Analysis (Additional Insight)
12.1 Very Small Companies
12.2 Small Companies
12.3 Mid-Sized Companies
12.4 Large Companies
12.5 Very Large Companies
13 Payment Methods (Additional Insight)
13.1 Government Funded
13.2 Private Insurance
13.3 Out-of-Pocket

Companies Mentioned

  • PAREXEL International Corporation
  • Thermo Fischer Scientific, Inc.
  • SGS SA
  • ICON plc
  • Medpace Australia Pty. Ltd
  • Charles River Laboratories International, Inc.
  • IQVIA
  • Novotech
  • Laboratory Corporation of America Holdings
  • Syneos Health